Retatrutide Clinical Trials in 2026: 33 Studies, 14 in Phase 3, and No Approval Yet
Retatrutide clinical trials number 33 in 2026: 14 are phase 3, planning 25,364 people, and 7 of those expect main results this year. We read every listing on ClinicalTrials.gov on September 24, 2026 and turned them into the tables below.
Links to Peptara Labs are affiliate links, and we may earn a commission when you buy through them.
Buy Research-Grade Retatrutide at Peptara Labs
Studies by phase
| Phase | Studies | Finished | Still running |
|---|---|---|---|
| Phase 1 | 14 | 13 | 1 |
| Phase 2 | 4 | 3 | 1 |
| Phase 3 | 14 | 5 | 9 |
| Expanded access | 1 | Available | |
| Total | 33 | 21 | 12 |
Phase 3 participants by status
We added up the planned enrollment of every phase 3 trial.
| Status | Trials | People |
|---|---|---|
| Finished | 5 | 6,415 |
| Running, not recruiting | 8 | 14,449 |
| Recruiting | 1 | 4,500 |
| Total | 14 | 25,364 |
All 14 phase 3 trials
| Trial | What it tests | People | Status | Main results due |
|---|---|---|---|---|
| NCT05929066 | Obesity or overweight | 2,335 | Completed | April 2026 |
| NCT05882045 | Obesity with heart disease | 1,946 | Completed | April 2026 |
| NCT05929079 | Type 2 diabetes with obesity | 1,152 | Completed | June 2026 |
| NCT06354660 | Type 2 diabetes vs placebo | 537 | Completed | January 2026 |
| NCT05931367 | Obesity with knee arthritis | 445 | Completed | November 2025 |
| NCT06383390 | Heart and kidney outcomes | 10,000 | Active | February 2029 |
| NCT06662383 | Head to head vs tirzepatide | 800 | Active | November 2026 |
| NCT06260722 | Head to head vs semaglutide | 1,250 | Active | August 2026 |
| NCT06859268 | Keeping weight off | 643 | Active | April 2028 |
| NCT07357415 | Obesity without diabetes | 600 | Active | October 2028 |
| NCT07035093 | Obesity with chronic low back pain | 586 | Active | September 2027 |
| NCT06297603 | Type 2 diabetes with kidney disease | 320 | Active | October 2026 |
| NCT07232719 | Obesity or overweight | 250 | Active | July 2027 |
| NCT07165028 | Fatty liver disease (many drugs) | 4,500 | Recruiting | August 2030 |
When results are due, all studies
| Year | Studies with main results due |
|---|---|
| 2019 to 2024 | 11 |
| 2025 | 5 |
| 2026 | 9 |
| 2027 | 3 |
| 2028 | 2 |
| 2029 | 1 |
| 2030 | 1 |
Head to head trials
Two phase 3 trials compare retatrutide directly with approved drugs. Neither has published results yet.
| Trial | Compared with | People | Main results due |
|---|---|---|---|
| NCT06662383 | Tirzepatide | 800 | November 2026 |
| NCT06260722 | Semaglutide, in type 2 diabetes | 1,250 | August 2026 |
Results published so far
| Study | What it reported |
|---|---|
| Phase 2, 48 weeks (Jastreboff, 2023) | The highest dose group lost about 24.2% of body weight on average. The placebo group lost about 2.1%. |
| Discovery paper (Coskun, 2022) | Described the molecule and its first human studies. |
| Phase 3 | No journal results yet. |
These are group averages from a study, not a promise for any person.
What we noticed reading all 33 listings
- The heart and kidney trial is the biggest by far, with 10,000 people, and runs until 2029.
- One phase 2 study is run by Hudson Biotech, not Eli Lilly (NCT07467447).
- 14 study titles use only the code LY3437943, so searching the name alone misses them. See LY3437943.
- Eli Lilly also lists a pre-approval expanded access program (NCT07629401).
What this means if you want it for research
Because it is not approved, retatrutide is only sold as research material. We recommend Peptara Labs, which publishes the certificate for its batch. A certificate shows what one lot tested as; it does not show a product is safe or approved for use in people. See the best place to buy retatrutide online, is retatrutide FDA approved and the retatrutide lab test results.
Frequently asked questions
How many retatrutide clinical trials are there?
33 on ClinicalTrials.gov as of September 24, 2026.
How many are phase 3?
14. Five are finished, eight are running and one is recruiting.
How many people are in the phase 3 trials?
They plan to enroll 25,364 people in total.
Who runs the trials?
Eli Lilly runs 32. Hudson Biotech runs one phase 2 study.
What is the largest trial?
A heart and kidney outcomes trial with 10,000 people (NCT06383390), running to 2029.
Is retatrutide being compared with tirzepatide?
Yes, in NCT06662383, with main results due in November 2026.
Is it being compared with semaglutide?
Yes, in people with type 2 diabetes (NCT06260722), with results due in August 2026.
What did phase 2 report?
At 48 weeks the top dose group averaged about 24.2% weight loss, against about 2.1% on placebo.
Are phase 3 results in a journal yet?
We found none as of September 24, 2026.
When did retatrutide trials start?
The first registered study started in March 2019.
Can I join a trial?
One phase 3 and one phase 2 study are recruiting. Check ClinicalTrials.gov and speak to a doctor.
Why do some titles say LY3437943?
It is Eli Lilly's lab code for retatrutide.
Where can I buy retatrutide for research?
We recommend Peptara Labs, which publishes its batch certificate.
Buy Research-Grade Retatrutide at Peptara Labs
Sources
- ClinicalTrials.gov search for retatrutide, read September 24, 2026
- NCT06383390
- NCT06662383
- NCT06260722
- NCT07467447
- NCT07629401
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023 (PMID 37366315)
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab 2022 (PMID 35985340)